Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer - Supplementary Material

Supplemental Table 1: PICOS criteria to identify and select trials for the SR
Supplemental Table 2. Search strategy for EMBASE 1974 to 2022 April 20
Supplemental Table 3. Search strategy for Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to April 19, 2022
Supplemental Table 4. Search strategy for EBM Reviews - Cochrane Central Register of Controlled Trials March 2022
Supplemental Table 5. List of included trials
Supplemental Table 6. Risk of bias assessment for included trials
Supplemental Table 7. Treatment characteristics of included trials
Supplemental Table 8. Patient characteristics in included trials
Supplemental Table 9. Survival outcome definitions in included trials
Supplemental Table 10. Reported overall and progression-free survival hazard ratios
Supplemental Table 11. Safety outcomes reported by included trials
Supplemental Table 12. Data sources and populations for network meta-analysis
Supplemental Table 13. Constant HRs for OS and PFS used in the network meta-analysis
Supplemental Table 14. Constant HRs for OS used in the sensitivity network meta-analysis excluding E2100 and MERiDiAN trials
Supplemental Table 15. Sensitivity network meta-analysis excluding E2100 and MERiDiAN trials